Derms on Drugs

Feeling a little worn down by Friday? A bit… degenerated, perhaps? This week’s Derms on Drugs goes off the beaten path and into the world of regenerative dermatology, where the line between legit science and “sounds like a scam” gets… blurry. With guest Dr. Amanda Hill, the team tackles hormones, skin aging, and whether we’re actually regenerating tissue—or just getting better at marketing it. From estrogen myths (and what we got very wrong) to PRP, exosomes, and the truth about “bioidentical” everything, this one separates hype from what might actually matter—and calls out a lot of nonsense along the way.

This week’s Derms on Drugs 6-pack moves past theory and into real decisions—what actually helps you pick the rightdrug for the patient in front of you. From gene expression profiling that predicts JAK vs Th2 response to the growing concern around dupilumab and CTCL, and more, this episode separates signal from noise—and gives you a few things you won’t forget (looking at you, abscopal effect).

Couldn’t make it to Denver for AAD—or made it to Part 1 but still hungry for the rest? Derms on Drugs is back with Part 2, finishing the job with more of the hottest late-breaking data in dermatology. Join Drs. Zirwas, Ferris, and Patton as they dive into the remaining abstracts, breaking down what actually matters (and what doesn’t) with the same unfiltered, practical take you expect from the DoD crew.

Couldn't make it to Denver for the AAD conference?  Made it to Denver but maybe had one too many Old Fashions to make it to the late breaking abstract presentations?  DoD may have had too many Old Fashions (it was really only Dr. Zirwas), but we still made it to the session with all the hottest data in the world of dermatology.  Join Drs. Zirwas, Ferris, and Patton for the first episode of this pair that'll keep you ahead of the curve.

Some studies make you rethink everything. Others… not so much. This week, it’s a classic Derms on Drugs 6-pack that sorts through what’s actually useful, what’s overhyped, and what might quietly change how you practice. Can Castle testing spare sentinel node biopsies—or not yet? And why U.S. derms (and Patton) disagree with Europe on BP guidance. Plus more!